Sales of major items owned by Viatris and Organon, which were spun off from Pfizer and MSD, are declining in the domestic outpatient prescription market.

As of last year, Viatris' outpatient prescriptions fell 4% and Organon's 6% YoY. The decline in prescription results for most major items, such as Viatris' Lipitor·Lyrica and Organon's Singulair·Cozaar, has not been avoided.

The prescription performance of the headquarters of Pfizer and MSD, which spun off its business divisions centering on patent-expired drugs, was relatively insignificant.

◆Viatris'L ipitor· Lyrica, 4% reduction in prescription performance

According to UBIST, a drug market research